Francesca Toffalorio

2.2k total citations · 2 hit papers
48 papers, 1.3k citations indexed

About

Francesca Toffalorio is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Francesca Toffalorio has authored 48 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Francesca Toffalorio's work include Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (17 papers) and Lung Cancer Diagnosis and Treatment (11 papers). Francesca Toffalorio is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (17 papers) and Lung Cancer Diagnosis and Treatment (11 papers). Francesca Toffalorio collaborates with scholars based in Italy, United States and Australia. Francesca Toffalorio's co-authors include Tommaso De Pas, Gianluca Spitaleri, Massimo Barberis, Chiara Catania, Angelo Delmonte, Pier Giuseppe Pelicci, Lorenzo Spaggiari, Filippo de Braud, Benjamin Solomon and Alice T. Shaw and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Francesca Toffalorio

46 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

2022 129 citations Benjamin Solomon, Todd M. Bauer et al. The Lancet Respiratory Medicine profile →
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

2024 118 citations Benjamin Solomon, Geoffrey Liu et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Francesca Toffalorio

Since Specialization

Citations

This map shows the geographic impact of Francesca Toffalorio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesca Toffalorio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesca Toffalorio more than expected).

Fields of papers citing papers by Francesca Toffalorio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesca Toffalorio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesca Toffalorio. The network helps show where Francesca Toffalorio may publish in the future.

Co-authorship network of co-authors of Francesca Toffalorio

This figure shows the co-authorship network connecting the top 25 collaborators of Francesca Toffalorio. A scholar is included among the top collaborators of Francesca Toffalorio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesca Toffalorio. Francesca Toffalorio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study breakdown → 2024 ·Journal of Clinical Oncology ·Benjamin Solomon, Geoffrey Liu, Enriqueta Felip, Tony Mok, Ross A. Soo, Julien Mazières, Alice T. Shaw, Filippo de Marinis, Yasushi Goto, Yi‐Long Wu, Dong‐Wan Kim, Jean-François Martini, Rossella Messina, Jolanda Paolini, Anna Polli, Despina Thomaidou, Francesca Toffalorio, Todd M. Bauer	118
2	Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report 2024 ·Journal of Thoracic Oncology ·Sai‐Hong Ignatius Ou, Benjamin Solomon, Benjamin Besse, Alessandra Bearz, Chia‐Chi Lin, Rita Chiari, D. Ross Camidge, (unknown), Antonello Abbattista, Francesca Toffalorio, Ross A. Soo	6
3	Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer 2024 ·Future Oncology ·Benjamin Solomon, Geoffrey Liu, Enriqueta Felip, Tony Mok, Ross A. Soo, Julien Mazières, Alice T. Shaw, Filippo de Marinis, Yasushi Goto, Yi‐Long Wu, Dong‐Wan Kim, Jean-François Martini, Rossella Messina, Jolanda Paolini, Anna Polli, Despina Thomaidou, Francesca Toffalorio, Todd M. Bauer	0
4	Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC 2023 ·Journal of Thoracic Oncology ·Ross A. Soo, Jean‐François Martini, Anthonie J. van der Wekken, Shunsuke Teraoka, Roberto Ferrara, Alice T. Shaw, (unknown), Anna Maria Calella, Anna Polli, Francesca Toffalorio, Pascale Tomasini, Chao‐Hua Chiu, Dariusz M. Kowalski, Hye Ryun Kim, Benjamin Solomon	22
5	Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer 2023 ·Future Oncology ·Benjamin Solomon, Todd M. Bauer, Tony Mok, Geoffrey Liu, Julien Mazières, Filippo de Marinis, Yasushi Goto, Dong‐Wan Kim, Yi‐Long Wu, Jacek Jassem, (unknown), Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip	0
6	Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial 2022 ·Lung Cancer ·Ross A. Soo, Eng Huat Tan, Hidetoshi Hayashi, Takashi Seto, Chia‐Chi Lin, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Geoffrey Liu, Antonello Abbattista, Jean-François Martini, (unknown), Francesca Toffalorio, Benjamin Solomon	13
7	Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study breakdown → 2022 ·The Lancet Respiratory Medicine ·Benjamin Solomon, Todd M. Bauer, Tony Mok, Geoffrey Liu, Julien Mazières, Filippo de Marinis, Yasushi Goto, Dong‐Wan Kim, Yi‐Long Wu, Jacek Jassem, (unknown), Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip	129
8	Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs 2021 ·Annals of Oncology ·Enriqueta Felip, Alice T. Shaw, Alessandra Bearz, D. Ross Camidge, Benjamin Solomon, Jessica R. Bauman, Todd M. Bauer, Solange Peters, Francesca Toffalorio, Antonello Abbattista, Holger Thurm, Gerson Peltz, Robin Wiltshire, Benjamin Besse	68
9	1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression 2020 ·Annals of Oncology ·Sai‐Hong Ignatius Ou, Benjamin Solomon, Alice T. Shaw, (unknown), Benjamin Besse, Ross A. Soo, Antonello Abbattista, Holger Thurm, Francesca Toffalorio, Robin Wiltshire, Alessandra Bearz	1
10	A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors 2019 ·Journal for ImmunoTherapy of Cancer ·Ezra E.W. Cohen, Michael J. Pishvaian, Dale R. Shepard, Ding Wang, Jared Weiss, Melissa L. Johnson, Christine H. Chung, Ying Chen, Bo Huang, Craig B. Davis, Francesca Toffalorio, Aron D. Thall, Steven Powell	45
11	Molecular Features and Clinical Outcome of Lung Malignancies in Very Young People 2015 ·Future Oncology ·Chiara Catania, Edoardo Botteri, Massimo Barberis, Fabio Conforti, Francesca Toffalorio, Filippo de Marinis, S. Boselli, Cristina Noberasco, Angelo Delmonte, Gianluca Spitaleri, Lorenzo Spaggiari, Nicole Rotmensz, Antonio Passaro, Barbara Bazolli, M. Alfieri, Michela Manzotti, Caterina Fumagalli, Alessandra Milani, Tommaso De Pas	11
12	Erlotinib Efficacy in NSCLC Patients with High Polysomy of Chromosome 7 and EGFR/KRas Wild-Type Tumors 2015 ·Journal of Thoracic Oncology ·Francesca Toffalorio, Filippo de Marinis, Fabio Conforti, Gianluca Spitaleri, Chiara Catania, Cristina Noberasco, Chiara Lazzari, Fabio Maria Vecchio, (unknown), Massimo Barberis, Tommaso De Pas	4
13	Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to “Work it Out”? 2014 ·Current Pharmaceutical Design ·Elena Galvani, Francesca Toffalorio, Godefridus J. Peters, Tommaso Martino De Pas, Elisa Giovannetti	4
14	Breast phyllodes tumor: A review of literature and a single center retrospective series analysis 2013 ·Critical Reviews in Oncology/Hematology ·Gianluca Spitaleri, Antonio Toesca, Edoardo Botteri, Luca Bottiglieri, Nicole Rotmensz, S. Boselli, Claudia Sangalli, Chiara Catania, Francesca Toffalorio, Cristina Noberasco, Angelo Delmonte, Alberto Luini, Paolo Veronesi, Marco Colleoni, Giuseppe Viale, Stefano Zurrida, Aron Goldhirsch, Umberto Veronesi, Tommaso De Pas	141
15	Targeting ALK in patients with advanced Non Small Cell Lung Cancer: Biology, diagnostic and therapeutic options 2013 ·Critical Reviews in Oncology/Hematology ·Chiara Lazzari, Gianluca Spitaleri, Chiara Catania, Massimo Barberis, Cristina Noberasco, Mariacarmela Santarpía, Angelo Delmonte, Francesca Toffalorio, Fabio Conforti, Tommaso Martino De Pas	23
16	TRIM Proteins in Cancer 2012 ·Advances in experimental medicine and biology ·Valeria Cambiaghi, Virginia Giuliani, Sara Lombardi, (unknown), Francesca Toffalorio, Pier Giuseppe Pelicci	122
17	Vaccines in non-small cell lung cancer: Rationale, combination strategies and update on clinical trials 2012 ·Critical Reviews in Oncology/Hematology ·Tommaso De Pas, Monica Giovannini, María Rescigno, Chiara Catania, Francesca Toffalorio, Gianluca Spitaleri, Angelo Delmonte, Massimo Barberis, Lorenzo Spaggiari, Piergiorgio Solli, Paolo Veronesi, Filippo de Braud	24
18	Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations 2011 ·Journal of Thoracic Oncology ·Tommaso De Pas, Francesca Toffalorio, Michela Manzotti, Caterina Fumagalli, Gianluca Spitaleri, Chiara Catania, Angelo Delmonte, Monica Giovannini, Lorenzo Spaggiari, Filippo de Braud, Massimo Barberis	106
19	A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma 2010 ·Acta Oncologica ·Chiara Catania, Giuseppe Pelosi, Nicola Fazio, Roberto Biffi, Gianluca Spitaleri, Cristina Noberasco, (unknown), Angelo Maggioni, Giuseppe Trifirò, Francesca Toffalorio, Paolo Della Vigna, Filippo de Braud, Tommaso De Pas	3
20	Brief Report: Activity of Imatinib in a Patient with Platelet-Derived-Growth-Factor Receptor Positive Malignant Solitary Fibrous Tumor of the Pleura 2008 ·Journal of Thoracic Oncology ·Tommaso De Pas, Francesca Toffalorio, Piergiuseppe Colombo, Giuseppe Trifirò, Giuseppe Pelosi, Paolo Della Vigna, Michela Manzotti, (unknown), Filippo de Braud	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact